News By Tag
* Inspire Pharmaceuticals
* Buy Out
* More Tags...
News By Location
Inspire Pharmaceuticals, Inc. Takeover under Investor Investigation
The Shareholders Foundation announces that an investigation for investors in Inspire Pharmaceuticals, Inc. was announced and NASDAQ-ISPH stockholders should email to email@example.com
If you purchased Inspire Pharmaceuticals, Inc. and currently continue to hold those NASDAQ-ISPH shares, and/or if you have any information relating the investigation, you have certain options and you should contact the Shareholders Foundation at firstname.lastname@example.org or call +1(858) 779 - 1554.
The investigations by law firms concern whether certain directors and officers at Inspire Pharmaceuticals, Inc. (Public, NASDAQ-ISPH)
On Tuesday, April 5, 201, Inspire Pharmaceuticals, Inc. and Merck announced that they have entered into an agreement under which Merck will acquire Inspire Pharmaceuticals, Inc in a transaction that has a total cash value of approximately $430 million. Under the terms of the proposed takeover, Merck, through a subsidiary, will commence a tender offer for all outstanding common stock of Inspire Pharmaceuticals, Inc at a price of $5.00 per ISPH share in cash.
Inspire Pharmaceuticals, Inc.said the offer represents a 26% premium to the closing price of Inspire Pharmaceuticals' common stock on April 4, 2011.
In response to the takeover announcement ISPH shares increased from slightly under $4 on April 4, 2011 to $4.97 on April 5.
However shares of Inspire Pharmaceuticals, Inc. traded as high as $8.08 per share in December 2010. In addition, at least on analyst has set a target price of $10.00 per share for Inspire Pharmaceuticals stock. Furthermore Inspire Pharmaceuticals financially performed well for its investors. Inspire Pharmaceuticals’
Therefore the investigation concerns whether the Inspire Pharmaceuticals Board of Directors undertook an adequate and fair sales process to obtain fair consideration for all shareholders of Inspire Pharmaceuticals, Inc. and breached their fiduciary duties to Inspire Pharmaceuticals (ISPH) shareholder by failing to adequately shop the Company before entering into any transaction.
The investigation concerns also whether Merck, through a subsidiary, would underpay for NASDAQ-ISPH shares, thus unlawfully harming ISPH stockholders. A potential class action lawsuit would seek to maximize the amount of money and information Inspire Pharmaceuticals shareholders would receive in a buyout, so the law firm.
Those who purchased Inspire Pharmaceuticals, Inc. (Public, NASDAQ-ISPH)
# # #
The Shareholders Foundation, Inc. is an investor advocacy group. We do research related to shareholder issues and inform investors of securities class actions, settlements, judgments, and other legal related news to the stock/financial market. At Shareholders Foundation, Inc. we are in contact with a large number of shareholders. We believe that together we can combine the interests of many investors, and use the size of our interest as leverage against the giant corporations. We offer help, support, and assistance for every shareholder. We help investors find answers to their questions and equitable solutions to their problems. The Shareholders Foundation, Inc. is not a law firm. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.